<DOC>
	<DOCNO>NCT02559674</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , multi-center , competitive enrollment dose escalation study ALT-803 combination gemcitabine nab-paclitaxel patient advanced pancreatic cancer conjunction gemcitabine nab-paclitaxel .</brief_summary>
	<brief_title>QUILT-2.001 : ALT-803 Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine Nab-Paclitaxel</brief_title>
	<detailed_description>The purpose study evaluate safety tolerability escalate dos , identify Maximum Tolerated Dose ( MTD ) designate dose level Phase II study ( RP2D ) ALT-803 administer combination gemcitabine nab-paclitaxel patient advanced pancreatic cancer . To access anti-tumor activity ALT-803 administer combination gemcitabine nab-paclitaxel measure objective response rate , overall survival , progression-free survival , time progression , duration response patient advance pancreatic cancer . To Characterize pharmacokinetic , immunogenicity , serum cytokine profile ALT-803 combination gemcitabine nab-paclitaxel treated patient . To correlate circulate cell free DNA circulate tumor DNA clinical outcome study treated patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis pancreatic cancer . For dose escalation phase ( Phase Ib ) distant metastatic disease unresectable disease candidate stag resection . For expansion phase ( Phase II ) distant metastatic disease . For dose escalation phase ( Phase Ib ) 0 1 prior line chemotherapy advance pancreatic cancer . Prior gemcitabine allow , however prior nabpaclitaxel allow . For expansion phase ( Phase II ) prior therapy pancreatic cancer allow except adjuvant therapy long complete ≥ 6 month prior study treatment start Have least one untreated progress tumor lesion accurately measure accord Response Evaluation Criteria Solid Tumor Prior radiation allow index lesion ( ) remain outside treatment field progress since prior treatment . Radiation therapy must complete least 4 week prior baseline scan Resolved acute effect prior therapy baseline Grade ≤1 The Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Life expectancy ≥12 week Glomerular Filtration Rate ( GFR ) &gt; 40mL ( milliliter ) /min ; Creatinine ≤ 1.5 x ULN ( Upper limit Normal ) Platelets ≥100,000/uL ( microliter ) Hemoglobin ≥ 9g/dL Absolute Lymphocytes ≥800/uL Absolute neutrophil count/absolute granulocyte count ≥1500/uL Total bilirubin ≤ 2.0 X ULN , ≤ 3.0 X ULN ( patient Gilbert 's Syndrome ) aspartate aminotransferase , alanine aminotransferase ≤ 2.5 X ULN , ≤ 5.0 X ULN ( liver metastasis present ) Normal clinical assessment pulmonary function Negative serum pregnancy test female childbearing potential Subjects , female male , reproductive potential must agree use effective contraceptive measure duration study Must provide inform consent HIPPA authorization agree comply protocolspecified procedure followup evaluation No woman pregnant nursing No known hypersensitivity gemcitabine nabpaclitaxel No concurrent herbal unconventional therapy No prior therapy IL15 IL15 analog No ongoing toxicity prior anticancer treatment may interfere study treatment . All toxicity attribute prior anticancer therapy alopecia fatigue must resolve grade 1 baseline administration study treatment . No positive Hep C serology active Hep B infection No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia severe cardiac dysfunction No history uncontrollable supraventricular arrhythmia No New York Heart Association Class &gt; II congestive heart failure No mark baseline prolongation QT/QTc interval No know autoimmune disease require active treatment . Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day enrollment . Inhaled topical steroid , adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent , permit absence active autoimmune disease No know prior organ allograft allogeneic transplantation No known HIVpositive AIDS unless patient stable highly active antiretroviral therapy ( HAART ) regimen , CD4 ( cluster differentiation 4 ) count &gt; 350 , detectable viral load quantitative polymerase chain reaction test No untreated central nervous system metastasis , treat must neurologically stable least 2 week prior enrollment No corticosteroid , stable decrease dose ≤ 10 mg daily prednisone ( equivalent ) No psychiatric illness/social situation would limit compliance No illness opinion investigator would exclude subject participate study No active systemic infection require parenteral antibiotic therapy No anticancer treatment include surgery , radiotherapy , chemotherapy , immunotherapy , investigational therapy within 14 day treatment start No disease require systemic immunosuppressive therapy No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 3 year surgical treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced Pancreatic Cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Immunotherapeutic</keyword>
	<keyword>Interleukin-15</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Metastatic Disease</keyword>
	<keyword>Combination Immunotherapy</keyword>
</DOC>